المؤلفون: Villalobos VM; University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA., Mo G; Eli Lilly and Company, Indianapolis, IN, USA., Agulnik M; Division of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA., Pollack SM; Division of Oncology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA., Rushing DA; Simon Cancer Center Indiana University Medical Center, Indianapolis, IN, USA., Singh A; Division of Hematology-Oncology, University of California, Los Angeles, CA, USA., Van Tine BA; Division of Medical Oncology, Department of Internal Medicine, Siteman Cancer Center, St. Louis School of Medicine, St. Louis, MO, USA., McNaughton R; Eli Lilly and Company, Windlesham, Surrey, UK., Decker RL; Eli Lilly and Company, Indianapolis, IN, USA., Zhang W; Eli Lilly and Company, Indianapolis, IN, USA., Shahir A; Eli Lilly and Company, Windlesham, Surrey, UK., Cronier DM; Eli Lilly and Company, Indianapolis, IN, USA.

المصدر: Cancer medicine [Cancer Med] 2020 Feb; Vol. 9 (3), pp. 882-893. Date of Electronic Publication: 2019 Dec 10.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal/*administration & dosage , Antineoplastic Combined Chemotherapy Protocols/*pharmacokinetics , Doxorubicin/*pharmacokinetics , Sarcoma/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Disease Progression ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Drug Interactions ; Female ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Neoplasm Staging ; Sarcoma/diagnosis ; Sarcoma/mortality ; Sarcoma/pathology

المؤلفون: Jones RL; University of Washington and Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA. robin.Jones@rmh.nhs.uk.; Royal Marsden Hospital and Institute of Cancer Research, London, UK. robin.Jones@rmh.nhs.uk., Mo G; Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA., Baldwin JR; Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA., Peterson PM; Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA., Ilaria RL Jr; Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA.; Celgene, Summit, NJ, USA., Conti I; Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA.; EMD Serono Research & Development Institute, Billerica, MA, USA., Cronier DM; Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK.; Merck Serono Ltd, Feltham, UK., Tap WD; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, 1275 York Ave, New York, NY, 10065, USA.

المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2019 Jan; Vol. 83 (1), pp. 191-199. Date of Electronic Publication: 2018 Nov 08.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Sarcoma/*mortality, Antibodies, Monoclonal/administration & dosage ; Doxorubicin/administration & dosage ; Follow-Up Studies ; Humans ; Prognosis ; Sarcoma/drug therapy ; Sarcoma/pathology ; Survival Rate

المؤلفون: Mo G; Eli Lilly and Company, Indianapolis, IN, USA. gary.mo@lilly.com., Baldwin JR; Eli Lilly and Company, Indianapolis, IN, USA., Luffer-Atlas D; Eli Lilly and Company, Indianapolis, IN, USA., Ilaria RL Jr; Eli Lilly and Company, Indianapolis, IN, USA., Conti I; Eli Lilly and Company, Indianapolis, IN, USA., Heathman M; Eli Lilly and Company, Indianapolis, IN, USA., Cronier DM; Eli Lilly and Company, Indianapolis, IN, USA.

المصدر: Clinical pharmacokinetics [Clin Pharmacokinet] 2018 Mar; Vol. 57 (3), pp. 355-365.

نوع المنشور: Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print Cited Medium: Internet ISSN: 1179-1926 (Electronic) Linking ISSN: 03125963 NLM ISO Abbreviation: Clin Pharmacokinet Subsets: MEDLINE

مواضيع طبية MeSH: Models, Biological*, Antibodies, Monoclonal/*administration & dosage , Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/pharmacokinetics ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Body Weight ; Disease-Free Survival ; Dose-Response Relationship, Drug ; Doxorubicin/administration & dosage ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasms/pathology ; Nonlinear Dynamics ; Receptor, Platelet-Derived Growth Factor alpha/antagonists & inhibitors ; Survival Rate ; Time Factors ; Young Adult

المؤلفون: Tate SC; Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK. tate_sonya@lilly.com., Sykes AK; Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK., Kulanthaivel P; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA., Chan EM; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA., Turner PK; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA., Cronier DM; Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK.

المصدر: Clinical pharmacokinetics [Clin Pharmacokinet] 2018 Mar; Vol. 57 (3), pp. 335-344.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print Cited Medium: Internet ISSN: 1179-1926 (Electronic) Linking ISSN: 03125963 NLM ISO Abbreviation: Clin Pharmacokinet Subsets: MEDLINE

مواضيع طبية MeSH: Models, Biological*, Aminopyridines/*administration & dosage , Antineoplastic Agents/*administration & dosage , Benzimidazoles/*administration & dosage , Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Aminopyridines/pharmacokinetics ; Aminopyridines/pharmacology ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Agents/pharmacology ; Benzimidazoles/pharmacokinetics ; Benzimidazoles/pharmacology ; Biological Availability ; Body Weight ; Cyclin-Dependent Kinase 4/antagonists & inhibitors ; Cyclin-Dependent Kinase 6/antagonists & inhibitors ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Male ; Middle Aged ; Neoplasms/pathology ; Sex Factors ; Young Adult

المؤلفون: Gerber DE; The University of Texas, Southwestern Medical Center at Dallas, Harry Hines Blvd., Mail Code 8852, Dallas, TX 75390-8852, USA. Electronic address: david.gerber@utsouthwestern.edu., Swanson P; Hematology/Oncology Associates of the Treasure Coast, Port Saint Lucie, FL 34952, USA. Electronic address: paulmswanson@msn.com., Lopez-Chavez A; Oregon Health and Science University, Portland, OR 97239, USA. Electronic address: lopezcha@ohsu.edu., Wong L; Scott & White Clinic, Hematology-Oncology, Temple, TX 76508, USA. Electronic address: lwong@sw.org., Dowlati A; Case Western Reserve University, Cleveland, OH 44106, USA. Electronic address: afshin.dowlati@case.edu., Pennell NA; Cleveland Clinic, Cleveland, OH 44195, USA. Electronic address: penneln@ccf.org., Cronier DM; Eli Lilly and Company, Windlesham GU20 6PH, UK. Electronic address: cronier_damien@lilly.com., Qin A; Eli Lilly and Company, Bridgewater, NJ 08807, USA. Electronic address: amy.qin@lilly.com., Ilaria R Jr; Eli Lilly and Company, Indianapolis, IN 46285, USA. Electronic address: Ilaria_robert_l@lilly.com., Cosaert J; Sotio a.s., 170 00 Prague 7, Czech Republic. Electronic address: jan.cosaert2@gmail.com., Shahir A; Eli Lilly and Company, United Kingdom of Great Britain and Northern Ireland, UK., Baggstrom MQ; Washington University, St. Louis, MO 63130, USA. Electronic address: mbaggstr@dom.wustl.edu.

المصدر: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2017 Sep; Vol. 111, pp. 108-115. Date of Electronic Publication: 2017 Jul 18.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Carcinoma, Non-Small-Cell Lung/*drug therapy , Carcinoma, Non-Small-Cell Lung/*pathology , Lung Neoplasms/*drug therapy , Lung Neoplasms/*pathology, Aged ; Antibodies, Monoclonal/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Non-Small-Cell Lung/mortality ; Combined Modality Therapy ; Drug Administration Schedule ; Female ; Humans ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Neoplasm Staging ; Paclitaxel/administration & dosage ; Remission Induction ; Survival Analysis ; Treatment Outcome

المؤلفون: Raje NS; Massachusetts General Hospital, Boston, MA, USA., Moreau P; University Hospital Hôtel-Dieu, Nantes, France., Terpos E; National and Kapodistrian University of Athens School of Medicine, Athens, Greece., Benboubker L; Hôpital Bretonneau, Centre Hospitalier Régional Universitaire (CHRU), Tours, France., Grząśko N; Medical University of Lublin and Department of Haematology, St. John's Cancer Centre, Lublin, Poland., Holstein SA; Roswell Park Cancer Institute, Buffalo, NY, USA., Oriol A; Institut Català d'Oncologia (ICO) and Institut de Recerca contra la Leucèmia Josep Carreras (IJC), Hospital Germans Trias i Pujol, Badalona, Spain., Huang SY; National Taiwan University, Medical College and Hospital, Taipei, Taiwan., Beksac M; Ankara University Ibn Sina Hospital, Ankara, Turkey., Kuliczkowski K; Wroclaw Medical University, Wroclaw, Poland., Tai DF; Eli Lilly and Company, Indianapolis, IN, USA., Wooldridge JE; Eli Lilly and Company, Indianapolis, IN, USA., Conti I; Eli Lilly and Company, Indianapolis, IN, USA., Kaiser CJ; Eli Lilly and Company, Indianapolis, IN, USA., Nguyen TS; Eli Lilly and Company, Indianapolis, IN, USA., Cronier DM; Eli Lilly and Company Limited, Windlesham, Surrey, UK., Palumbo A; Myeloma Unit, Division of Haematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.

المصدر: British journal of haematology [Br J Haematol] 2017 Mar; Vol. 176 (5), pp. 783-795. Date of Electronic Publication: 2016 Dec 22.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal/*administration & dosage , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Multiple Myeloma/*drug therapy, Adult ; Aged ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/administration & dosage ; Dexamethasone/administration & dosage ; Disease-Free Survival ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/complications ; Multiple Myeloma/mortality ; Salvage Therapy/methods ; Treatment Outcome

المؤلفون: Raje NS; Massachusetts General Hospital, Boston, Massachusetts. NRAJE@mgh.harvard.edu., Faber EA Jr; University of Nebraska Medical Center, Omaha, Nebraska., Richardson PG; Dana Farber Cancer Institute, Boston, Massachusetts., Schiller G; David Geffen School of Medicine at UCLA, Los Angeles, California., Hohl RJ; University of Iowa Hospitals and Clinics, Iowa City, Iowa., Cohen AD; Fox Chase Cancer Center, Philadelphia, Pennsylvania., Forero A; University of Alabama at Birmingham, Birmingham, Alabama., Carpenter S; Eli Lilly and Company, Indianapolis, Indiana., Nguyen TS; Eli Lilly and Company, Indianapolis, Indiana., Conti I; Eli Lilly and Company, Indianapolis, Indiana., Kaiser CJ; Eli Lilly and Company, Indianapolis, Indiana., Cronier DM; Eli Lilly and Company, Indianapolis, Indiana., Wooldridge JE; Eli Lilly and Company, Indianapolis, Indiana., Anderson KC; Dana Farber Cancer Institute, Boston, Massachusetts.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2016 Dec 01; Vol. 22 (23), pp. 5688-5695. Date of Electronic Publication: 2016 Jun 10.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal/*therapeutic use , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , B-Cell Activating Factor/*metabolism , Bortezomib/*therapeutic use , Multiple Myeloma/*drug therapy , Neoplasm Recurrence, Local/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents/therapeutic use ; B-Lymphocytes/drug effects ; B-Lymphocytes/metabolism ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/metabolism ; Neoplasm Recurrence, Local/metabolism

المؤلفون: Tap WD; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. Electronic address: tapw@mskcc.org., Jones RL; University Washington, Seattle, WA, USA; The Royal Marsden Hospital, London, UK., Van Tine BA; Washington University in St Louis, St Louis, MO, USA., Chmielowski B; UCLA Medical Center, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA., Elias AD; University of Colorado Cancer Center, Aurora, CO, USA., Adkins D; Washington University in St Louis, St Louis, MO, USA., Agulnik M; Northwestern University, Chicago, IL, USA., Cooney MM; University Hospitals Case Medical Center, Seidman Cancer Center, Division of Hematology and Oncology, Cleveland, OH, USA., Livingston MB; Carolinas Healthcare System, The Charlotte-Mecklenburg Hospital Authority, Charlotte, NC, USA., Pennock G; Baptist MD Anderson Cancer Center, Jacksonville, FL, USA., Hameed MR; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Shah GD; Novartis Pharmaceuticals, East Hanover, NJ, USA., Qin A; Eli Lilly and Company, Bridgewater, NJ, USA., Shahir A; Eli Lilly and Company, Windlesham, Surrey, UK., Cronier DM; Eli Lilly and Company, Windlesham, Surrey, UK., Ilaria R Jr; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Conti I; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Cosaert J; Eli Lilly and Company, Bridgewater, NJ, USA., Schwartz GK; Columbia University School of Medicine, New York, NY, USA.

المصدر: Lancet (London, England) [Lancet] 2016 Jul 30; Vol. 388 (10043), pp. 488-97. Date of Electronic Publication: 2016 Jun 09.

نوع المنشور: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

مواضيع طبية MeSH: Antibiotics, Antineoplastic/*therapeutic use , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Doxorubicin/*therapeutic use , Sarcoma/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antibiotics, Antineoplastic/administration & dosage ; Antibodies, Monoclonal/administration & dosage ; Disease-Free Survival ; Doxorubicin/administration & dosage ; Drug Administration Schedule ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Patient Selection ; Treatment Outcome ; United States

المؤلفون: Patnaik A; South Texas Accelerated Research Therapeutics, San Antonio, Texas. amita.patnaik@start.stoh.com geoffrey_shapiro@dfci.harvard.edu., Rosen LS; University of California, Los Angeles, California., Tolaney SM; Dana-Farber Cancer Institute, Boston, Massachusetts., Tolcher AW; South Texas Accelerated Research Therapeutics, San Antonio, Texas., Goldman JW; University of California, Los Angeles, California., Gandhi L; Dana-Farber Cancer Institute, Boston, Massachusetts., Papadopoulos KP; South Texas Accelerated Research Therapeutics, San Antonio, Texas., Beeram M; South Texas Accelerated Research Therapeutics, San Antonio, Texas., Rasco DW; South Texas Accelerated Research Therapeutics, San Antonio, Texas., Hilton JF; Dana-Farber Cancer Institute, Boston, Massachusetts., Nasir A; Eli Lilly and Company, Indianapolis, Indiana., Beckmann RP; Eli Lilly and Company, Indianapolis, Indiana., Schade AE; Eli Lilly and Company, Indianapolis, Indiana., Fulford AD; Eli Lilly and Company, Indianapolis, Indiana., Nguyen TS; Eli Lilly and Company, Indianapolis, Indiana., Martinez R; Eli Lilly and Company, Indianapolis, Indiana., Kulanthaivel P; Eli Lilly and Company, Indianapolis, Indiana., Li LQ; Eli Lilly and Company, Indianapolis, Indiana., Frenzel M; Eli Lilly and Company, Indianapolis, Indiana., Cronier DM; Eli Lilly and Company, Indianapolis, Indiana., Chan EM; Eli Lilly and Company, Indianapolis, Indiana., Flaherty KT; Massachusetts General Hospital, Boston, Massachusetts., Wen PY; Dana-Farber Cancer Institute, Boston, Massachusetts., Shapiro GI; Dana-Farber Cancer Institute, Boston, Massachusetts. amita.patnaik@start.stoh.com geoffrey_shapiro@dfci.harvard.edu.

المصدر: Cancer discovery [Cancer Discov] 2016 Jul; Vol. 6 (7), pp. 740-53. Date of Electronic Publication: 2016 May 23.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE

مواضيع طبية MeSH: Aminopyridines/*therapeutic use , Antineoplastic Agents/*therapeutic use , Benzimidazoles/*therapeutic use , Cyclin-Dependent Kinase 4/*antagonists & inhibitors , Cyclin-Dependent Kinase 6/*antagonists & inhibitors , Neoplasms/*drug therapy, Aminopyridines/administration & dosage ; Aminopyridines/adverse effects ; Aminopyridines/pharmacokinetics ; Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Benzimidazoles/administration & dosage ; Benzimidazoles/adverse effects ; Benzimidazoles/pharmacokinetics ; Breast Neoplasms/diagnosis ; Breast Neoplasms/drug therapy ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Disease Models, Animal ; Drug Monitoring ; Female ; Humans ; Lung Neoplasms/diagnosis ; Lung Neoplasms/drug therapy ; Male ; Mice ; Molecular Targeted Therapy ; Neoplasm Metastasis ; Neoplasm Staging ; Neoplasms/diagnosis ; Neoplasms/mortality ; Tomography, X-Ray Computed ; Treatment Outcome ; Xenograft Model Antitumor Assays

المؤلفون: Tate SC; Global PK/PD, Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK., Burke TF; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA., Hartman D; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA., Kulanthaivel P; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA., Beckmann RP; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA., Cronier DM; Global PK/PD, Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK.

المصدر: British journal of cancer [Br J Cancer] 2016 Mar 15; Vol. 114 (6), pp. 669-79.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Melanoma/*drug therapy, Aminopyridines/administration & dosage ; Animals ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Benzimidazoles/administration & dosage ; Biomarkers, Tumor/metabolism ; Cell Line, Tumor ; Drug Administration Schedule ; Drug Resistance, Neoplasm ; Humans ; Indoles/administration & dosage ; Indoles/pharmacokinetics ; Melanoma/enzymology ; Melanoma/genetics ; Melanoma/metabolism ; Mice ; Models, Biological ; Mutation ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins B-raf/metabolism ; Sulfonamides/administration & dosage ; Sulfonamides/pharmacokinetics ; Vemurafenib ; Xenograft Model Antitumor Assays